Sanjivani Paranteral Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹16Cr
- −14.5% YoY
- −13.4% QoQ
- Net profit
- ₹2Cr
- −28.7% YoY
- −5.2% QoQ
- Margin
- 14.52%
- −1.2 pp YoY
- −0.2 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions. The company expects a minimum of 10% sales growth for FY '26 compared to the previous year.
From Sanjivani Paranteral Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions.
- Pune plant to start contributing commercially from Q3 FY '26, with full-year revenue potential of INR 90-110 crores.
- Optimal capacity utilization of the Pune plant expected by Q2 FY '27, potentially contributing INR 20-25 crores quarterly.
- Base business growth projected at 15-20% for the next year (FY '27), with total revenue expected around INR 150 crores.
- Alevia Healthcare joint venture is forecasted to contribute INR 1-1.5 crores to the bottom line in FY '26 and expected to grow at least 100% in FY '27 (INR 3-3.5 crores+).
2 more points from Sanjivani Paranteral Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sanjivani Paranteral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- In H1 FY '26, Sanjivani Paranteral Limited undertook a capex of INR 1.04 crores.
- The company is modernizing its facilities, incorporating AI to enhance efficiency and cost-effectiveness.
- Development of import alternatives at the Pune plant is on track, with test licenses in place; products expected in the next 2-3 quarters.
- The Pune plant has started commercial production recently and is expected to contribute INR 90-110 crores revenue on full-year operation, hitting optimal capacity by Q2 FY '27.
2 more points from Sanjivani Paranteral Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanjivani Paranteral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Pune plant has a "very good healthy order book" in place, with commercial production started and business commencing from Q3 FY '26.
- Orders for the Pune plant come from semi-government, government institutions, and exports to 3-4 established geographies.
- Orders worth approximately INR 1 crore were held back due to local unrest in Nepal but have since been dispatched.
- Order books are reported to be good, supporting improved sales in the next two quarters.
2 more points from Sanjivani Paranteral Ltd's call on order book
Create a free account to keep reading this call
Sanjivani Paranteral Ltd — Quarterly revenue & net profit
Sanjivani Paranteral Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 16 | 18 | -14.5% | 18 | -13.4% |
| Operating profit (EBITDA) | 2 | 3 | -21.1% | 3 | -14.8% |
| Operating margin | 14.52% | 15.72% | -1.2 pp | 14.76% | -0.2 pp |
| Profit before tax | 2 | 3 | -24.7% | 2 | -4.8% |
| Net profit (PAT) | 2 | 2 | -28.7% | 2 | -5.2% |
| EPS (₹) | 1.34 | 1.97 | -32% | 1.43 | -6.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹11 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanjivani Paranteral's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sanjivani Paranteral Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sanjivani Paranteral Ltd Q2 FY26 results?
The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions. The company expects a minimum of 10% sales growth for FY '26 compared to the previous year.
What is Sanjivani Paranteral Ltd share price analysis?
Sanjivani Paranteral Ltd currently shows a neutral. The stock trades at a P/E of 35.2 with a market cap of ₹235 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sanjivani Paranteral Ltd planning capital expenditure?
In H1 FY '26, Sanjivani Paranteral Limited undertook a capex of INR 1.04 crores.
Keep Sanjivani Paranteral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
